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Abstract: Background: Pharmacological treatment is still the key intervention in the disease
management of long-term patients with schizophrenia; however, how it affects sleep and
whether gender differences exist remains unclear. Methods: Forty-six long-term outpatients with
schizophrenia entered the study. The numbers of antipsychotics, sleep medications, antidepressants,
and anxiolytics were analyzed. Moreover, all patients were tested using the Pittsburgh Sleep Quality
Index (PSQI) and the Epworth Sleepiness Scale (ESS). Correlation analyses were conducted between
the medication used and the scores on the two subjective sleep inventories. Results: A large variability,
ranging from 0 to 8, in the total number of psychiatric drugs per person was found between the
patients. Despite ongoing pharmacological treatment, the patients scored high on the PSQI, but not
on the ESS; this indicates that they report problems with sleep, but not with daytime sleepiness.
A significant positive correlation between the use of antipsychotics and the ESS score, but not the
PSQI score, was found; moreover, no gender differences were found. Conclusions: A large variability
exists in the pharmacological treatment of long-term patients with schizophrenia. To date, patients’
sleep problems have been insufficiently treated, and gender differences have not been adequately
accounted for in the pharmacological treatment of schizophrenia. More and larger international
clinical studies are warranted to verify the findings of the present preliminary pilot study before any
firm conclusions can be drawn and before any changes to the drug treatment of male and female
patients with schizophrenia can be recommended.
Keywords: schizophrenia; pharmacological treatment; sleep; sleep disturbances; sleep
disorders; gender
1. Introduction
Pharmacological treatment is still the key intervention in the disease management of patients
suffering from schizophrenia [1]. Antipsychotics are mostly prescribed to patients by their
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psychiatrists [2]. A distinction is made between the so-called first-generation antipsychotics that were
developed in the 1950s and the second-generation antipsychotics that were developed in the 1980s [3].
Examples of first-generation antipsychotics (sometimes referred to as conventional antipsychotics)
are haloperidol [4], chlorpromazine [5], fluphenazine [6], thiothixene [7], and perphenazine [8],
whereas examples of second-generation antipsychotics (sometimes called atypical antipsychotics)
commonly prescribed in the treatment of schizophrenia are risperidone [9], olanzapine [10],
quetiapine [11], aripiprazole [12], and asenapine [13].
Despite the pharmacologic advances in the treatment of patients with schizophrenia, important
issues still exist and need to be addressed in order to optimalize individual treatment [14]. One of
these issues is the large interindividual differences in the ways in which patients with schizophrenia
respond to antipsychotics [15]. Moreover, the optimal dose of a specific antipsychotic differs
markedly between patients, probably due to the patient’s unique genetic markers [15]; this needs
to be considered when developing an optimal treatment for each individual [16]. Both first- and
second-generation antipsychotics have important side effects that again differ between patients to a
large extent [15,17]. Previous research showed that first-generation antipsychotics have higher rates
and risks of extrapyramidal side effects than second-generation antipsychotics [18]. Second-generation
antipsychotics were developed in order to overcome those extrapyramidal side effects, and although
they partially succeeded [18], second-generation antipsychotics were unfortunately found to have
higher risks of causing metabolic side effects [19], weight gain [19], and cardiovascular problems [20].
Furthermore, they were unable to completely overcome the extrapyramidal side effects [2,18]. To sum
up, first-generation and second-generation antipsychotics are different in the ways they treat the
positive, negative, and cognitive symptoms of patients suffering from schizophrenia. With respect to
the efficacy on the individual level, large differences exist between persons; sometimes first-generation
antipsychotics are more efficient than second-generation antipsychotics and vice versa [21]. Moreover,
none of the abovementioned drugs has been found to be the gold standard, and although monotherapy
is recommended [22], polypharmacy is often used in daily clinical practice [22].
Besides the side effects mentioned above, antipsychotics also have an effect on the co-morbid
sleep disorders that often exist in patients with schizophremia [23]. Patients with schizophrenia
mostly show a longer sleep latency, a decrease in total sleep time, and a decrease in sleep
efficiency [24]. The underlying sleep architecture of patients with schizophrenia revealed reductions
in non-rapid-eye-movement sleep, slow-wave sleep, and rapid-eye-movement sleep latency [24].
In addition, rapid-eye-movement sleep duration was found to remain stable in patients with
schizophrenia [25]. Although the side effects of the medication can sometimes be beneficial [26], i.e.,
the patients start to sleep better [26], they can also be negative [26], i.e., the patients sleep worse [26].
So far, with respect to the effects of antipsychotics on sleep, it is known from electroencephalographic
sleep studies on healthy participants that the use of antipsychotic drugs, such as clozapine [27],
olanzapine [28], quetiapine [29], and ziprasidone [30], leads to an augmentation of sleep efficiency
and/or total sleep time [24,27–30]. In addition, previous research showed that olanzapine [28]
and ziprasidone [30] increased slow-wave sleep, but mixed results were found with respect to the
rapid-eye-movement results [24]. In patients with schizophrenia, it was found that the use of clozapine,
olanzapine, and paliperidone in most cases resulted in a significantly shorter sleep latency and a
significantly longer total sleep time as well as increased sleep efficiency [24]. Moreover, olanzapine [31]
and paliperidone [32] increased both slow-wave sleep and rapid-eye-movement sleep. In addition,
quetiapine was found to have a negative influence on sleep and resulted in a longer sleep latency,
wake time after sleep onset, and rapid-eye-movement sleep latency, as well as in a decrease of
slow-wave sleep and rapid-eye-movement sleep [33]. With respect to the effects of risperidone on
sleep, the results are as yet inconclusive [24]. Finally, it is important to note that so far, for several
antipsychotics, their effects on sleep in healthy individuals or patients with schizophrenia are either
insufficiently investigated and/or completely unknown.
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Although sleep disorders are increasingly recognized as a major problem for patients suffering
from schizophrenia [34] and normalized sleep has been found to be vital for a good clinical
outcome [35], in most cases, quality of sleep is not the direct focus of treatment [34]. Patients with
schizophrenia and co-morbid sleep disorders often receive antipsychotics, as well as pharmacological
treatment for their sleep disorders. Here, one can think of the following sleep medications that are
often prescribed: zopiclone [36], phenobarbitone [37], zolpidem [37], diazepam [37], etc. Unfortunately,
those sleep medications interact with the pharmacological treatment of the positive, negative, and
cognitive symptoms, which is the reason why determining optimal individual pharmacological
treatments for such patients is difficult. Pharmacological guidelines for treatment have been
developed [38], but recommendations vary in specificity [38]. Interestingly, when writing guidelines
for the treatment of these patients, concerns about side effects were found to be more important
than the efficacy of the medication [38]. Moreover, the choice and the dosage of the antipsychotic,
the duration of its use, and the way to handle treatment resistance should be investigated, as they have
been found to be often underestimated [38].
During the last decade, gender differences have finally received more attention in pharmacological
treatment [39]. Research has shown sex to be a risk factor regarding the side effects of medications [39].
However, most studies on antipsychotics still do not address the effects of the many potential
gender differences (e.g., differences in hormones, changes in hormone production throughout a
women’s life, etc.) on the efficacies of medications, the doses of medications, and other gender-specific
considerations [40]. At present, many gender issues are still under-investigated or not investigated at
all, and if a more optimal pharmacological treatment of patients with schizophrenia and co-morbid
sleep disorders is to be found, this gap of missing knowledge needs to be closed [40]. The question
arises as to whether gender differences can be found in practice when it comes to the antipsychotics
that are used.
The aim of the present study is to investigate the pharmacological treatment of long-term
outpatients with schizophrenia, how that treatment affects the subjective quality of sleep, and whether
gender differences exist. First, a large variability is expected to be found in the pharmacological
treatment of long-term patients with schizophrenia because, from the literature, patients with
schizophrenia are known to comprise a very heterogeneous clinical patient group. Second, based on
previous research, long-term patients with schizophrenia are hypothesized to suffer from sleep
problems. Third, an interaction between the pharmacological treatment and the subjective quality of
sleep is expected to exist; the more antipsychotic medications a long-term patient with schizophrenia
receives, the more daytime drowsiness will be reported. Our fourth hypothesis is that gender
differences will not be found in the pharmacological treatment regarding the numbers of drugs
the patients have been prescribed because, from the literature, gender differences are known to be often
unaccounted for in clinical research and daily clinical practice. Finally, the implications of our results
will be discussed and recommendations will be made for future research, as well as for clinical practice.
2. Materials and Methods
2.1. Participants
Forty-six long-term outpatients with schizophrenia were included in the study. They all signed
informed consent and their psychiatrists confirmed that they were able to do so. All patients
with schizophrenia were diagnosed by their psychiatrists in the clinic in accordance with The
ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic
Guidelines [41]. The patients included 20 males and 26 females. The patients had a mean length of
illness of 10.08 (SD = 5.25) years and a mean age of onset of disease of 32.75 (SD = 9.20) years. The male
patients had a mean age of 42.20 (SD = 9.49) years, and the female patients had a mean age of 43.31
(SD = 10.39) years. Because previous research found important age-related differences in quality of
sleep [42], testing for such differences was important. The Analysis of Variance (ANOVA), however,
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showed no significant difference in age between the male and the female groups (F(1,45) = 0.138,
p = 0.712, η2 = 0.003) in this study. Moreover, an ANOVA was conducted in order to test whether
differences in intelligence existed between the two groups, as intelligence might be a factor that
needs to be controlled in order to make the self-rating results of male and female patients with
schizophrenia on self-report questionnaires more reliable and comparable [43]. Intelligence was
measured using the Mehrfach-Wortschatz-Intelligenz-Test-B (MWT-B) [44]. The ANOVA results
proved that no significant difference in the mean intelligence scores between the male (M = 101.00,
SD = 15.65) and the female (M = 201.14, SD = 11.52) patient groups existed (F(1,38) = 0.068, p = 0.795,
η2 = 0.002). Exclusion criteria were other (besides the medications that are part of the individual
pharmacological treatment, caffeine, and/or nicotine use) addictive soft and hard drugs use, such as
cannabis, marijuana, cocaine, heroin, etc., and/or extensive alcohol use. All patients participated
on a voluntary basis, and none received a financial reward. The clinical study was approved
by the local ethics committee called Ärztekammer Nordrhein (under number: 2008331), and the
clinical trial was officially registered at the Dutch Trial Register (under number NTR3132/see
also http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3132). Finally, the Declaration of
Helsinki (http://www.wma.net/en/30publications/10policies/b3/) was followed during the conduct
of the study.
2.2. Pharmacological Data
The total numbers of medications, as well as the total numbers of antipsychotics, specific sleep
medication, evening sleep-enhancing medications, antidepressants, anxiolytics, and other medications,
were analyzed per patient. These data were available from a clinical database. The pharmacological
data for the participating outpatients was taken at the moment they entered the study.
2.3. Sleep Inventories
Two subjective sleep questionnaires were included in the study: The Pittsburgh Sleep Quality
Index (PSQI) [45] and the Epworth Sleepiness Scale (ESS) [46]. The PSQI [45] is a self-report instrument
with questions related to the individual’s sleep over the last four weeks. The instrument consists of
18 items and gathers information on the number of sleep disturbances, estimates on sleep quality,
sleep duration, sleep latency and sleep times, use of medication, and sleepiness during the day. The
items are summarized into seven components, each of which receives a score between 0 and 3. As a
result, the total score is a summation of the scores on those seven components and lies between 0 and
21. The higher the score, the poorer the individual’s sleep quality [45].
The ESS [46] is a self-report instrument consisting of eight questions. Individuals need to rate,
on a four-point scale (ranging from 0 = will never fall asleep to 3 = high probability of falling asleep),
the chances of dozing off or falling asleep while conducting eight different activities. Most individuals
participate in those eight activities on a regular basis; they do not need to be engaged in those activities
on a daily basis (examples are watching television, sitting in a room talking to somebody, etc.). The ESS
score is a summation of the scores on the eight items, and as a result, the ESS score lies somewhere
between 0 and 24. A high ESS score means a high ”daytime sleepiness”, and a low ESS score a low
“daytime sleepiness”. A score between 11 and 15 is considered to be a “mild-to-moderate” sleep apnea
while a score of 16 or above is considered to be a “severe” sleep apnea [46].
2.4. Procedure
The patients with schizophrenia voluntarily entered the study. First, they received general
information about the study and signed informed consent forms. This was followed by more specific
verbal and written instructions about the two specific sleep instruments, after which the patients
completed the PSQI [45] and the ESS [46], which took approximately 15 to 25 min, in a quiet room
in the clinic. A member of the staff was present in the room in case the patient had any questions.
After the completion of the two sleep instruments, all patients were debriefed.
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2.5. Statistics
Statistical Package for the Social Sciences (SPSS) version 22.0 (IBM Corp., Armonk, NY, USA,
2013) was used for all statistical analyses. An Analysis of Variance (ANOVA) was conducted to test
whether differences in scores on the two subjective sleep inventories existed between the male patient
group and the female patient group. Moreover, Pearson correlation analyses (two-tailed) were used to
test for a possible linear relationship between the patient’s subjective quality of sleep and the patient’s
pharmacological treatment. For all statistical analyses, a significance level of p < 0.05 was used [47].
3. Results
3.1. Total Medication Use
As can be seen in Table 1, in general, the long-term patients with schizophrenia received three
medications together. No difference could be found between male and female patients regarding
the mean number of medications received (F(1,45) = 0.008, p = 0.929, η2 = 0.000). The total number of
prescribed psychiatric medications varied between patients over a large range from zero up to even
eight different prescribed medications per patient.
Table 1. Overview of the average numbers of medications used by male and female long-term
outpatients suffering from schizophrenia.
Medication Total Male Group Female Group
Total number of medications 2.98 (SD = 1.90) 2.95 (SD = 2.01) 3.00 (SD = 1.84)
Number of antipsychotics 2.07 (SD = 1.30) 2.11 (SD = 1.37) 2.04 (SD = 1.27)
Number of specific sleep medications 0.05 (SD = 0.21) 0.11 (SD = 0.32) 0.00 (SD = 0.00)
Number of evening sleep-enhancing medications 0.84 (SD = 0.37) 0.84 (SD = 0.37) 0.83 (SD = 0.38)
Number of other medications 0.33 (SD = 0.57) 0.37 (SD = 0.60) 0.29 (SD = 0.55)
Number of antidepressants 0.44 (SD = 0.59) 0.37 (SD = 0.60) 0.50 (SD = 0.59)
Number of anxiolytics 0.07 (SD = 0.26) 0.00 (SD = 0.00) 0.13 (SD = 0.34)
3.2. Antipsychotic Medication
In general, patients with schizophrenia received 2.07 antipsychotics in the pharmacological
treatment of their positive, negative, and cognitive symptoms. Some patients received no antipsychotic
medication at all, whereas other patients received up to five different kinds of antipsychotics. In general,
the male patients received 2.11 antipsychotics versus 2.04 for the female patients. As can be seen in
Table 1, no significant difference in the number of prescribed antipsychotics between the male and
the female patients with schizophrenia was found (F(1,45) = 0.025, p = 0.875, η2 = 0.001). The most
frequently prescribed antipsychotics were quetiapine (13/46 = 28.26%), risperidone (13/46 = 28.26%),
and olanzapine (8/46 = 17.39%).
3.3. Sleep Medication
A close look at the use of sleep medication shows that only two patients (2/46 = 4.35%) received
a specific sleep medication; in both cases, the patients were male. However, an analysis of the male
and the female groups together showed no significant difference in sleep medication use (F(1,45) =
2.692, p = 0.108, η2 = 0.062) (see Table 1). The sleep medication that was prescribed was zopiclone
(2/46 = 4.35%). In most cases (39/46 = 84.78%), however, patients received other medications
(often antipsychotics) as a sleep-ameliorating drug in the evening. The frequency of this clinical
pharmacological intervention to improve sleep quality by using a non-specific sleep medication was
the same in the male and the female patients with schizophrenia (F(1,45) = 0.006, p = 0.940, η2 = 0.000)
(see also Table 1).
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3.4. Additional Medications
As can be seen in Table 1, in addition to the prescription of antipsychotics and sleep medications,
some patients with schizophrenia were prescribed antidepressants and anxiolytics. Again, the male
patients did not differ from the female patients regarding the use of antidepressants (F(1,45) = 0.522,
p = 0.474, η2 = 0.013) or anxiolytics (F(1,45) = 2.588, p = 0.115, η2 = 0.059).
3.5. Subjective Quality of Sleep Measurements
With respect to the scores on the two subjective sleep quality inventories, firstly, as can be seen in
Table 2, no significant difference in the mean total PSQI scores between the male patient group and
the female patient group was found (F(1,43) = 0.865, p = 0.358, η2 = 0.020). Both the male patient group
and the female patient group scored above the generally used cut-off score of 5 [45], as well as the
more recently used stricter cut-off score of 6 [48]. Two patients with schizophrenia (2/46 = 4.35%) were
unable to complete the PSQI. Secondly, no significant difference in the mean total ESS scores between
the male patient group and the female patient group was found (F(1,44) = 0.119, p = 0.732, η2 = 0.003).
Both the male patient group and the female patient group scored below the generally used cut-off
score of 9 [46]. One patient with schizophrenia (1/46 = 2.17%) was unable to complete the EES.
Table 2. Overview of the subjective sleep quality scores of the long-term outpatients with schizophrenia
on the The Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS) for the total
group, the male group, and the female group.
Sleep Inventories Total Male Group Female Group
PSQI 8.52 (SD = 4.70) 7.80 (SD = 4.69) 9.13 (SD = 4.72)
ESS 6.07 (SD = 4.01) 6.30 (SD = 4.18) 5.88 (SD = 3.95)
3.6. Interaction Effects between Pharmacological Treatment and Quality of Sleep
Correlation analyses on the medications used and the PSQI scores, as well as on the medications
used and the ESS scores, were conducted. The Pearson correlation analysis on the medications used
and the PSQI scores revealed no significant correlations between the number of antipsychotics and
the scores on the PSQI (r = −0.145, p = 0.364), the number of specific sleep medications and the scores
on the PSQI (r = 0.163, p = 0.310), or the total number of medications and the scores on the PSQI
(r = 0.025, p = 0.878). As to the Pearson correlation results for the medications used and the EES scores,
a significant positive correlation was found to exist between the number of antipsychotics and the score
on the ESS (r = 0.354, p = 0.021), but no significant correlations were found between the number of
specific sleep medications and the ESS scores (r = −0.201, p = 0.203) or the total number of medications
and the ESS scores (r = 0.252, p = 0.108).
4. Discussion
The aim of the present study was to investigate the pharmacological treatment of long-term
outpatients with schizophrenia, how that treatment affects the subjective quality of sleep, and whether
gender differences exist. First, we analyzed the pharmacological treatment of the patients. The
results clearly proved our expectation that a large variability existed in the pharmacological treatment
of long-term patients with schizophrenia. While some patients received no antipsychotics at all,
others received up to five different kinds of antipsychotics. Furthermore, the total number of psychiatric
medications ranged from zero up to even eight different medications. This finding stresses the
importance of both the implications for a patient of taking eight different medications each day and the
problem of all the different side effects, which are largely unknown, interacting with one another [49].
Moreover, cost-effectiveness studies on the efficiency of antipsychotic polytherapy versus antipsychotic
monotherapy for long-term patients with schizophrenia are lacking so far [50]. Those are needed in
Medicines 2018, 5, 44 7 of 13
the future in order to gain scientific proof for the often preferred antipsychotic polytherapy in daily
clinical practice, which was also found to be preferred in the present study and which is, in fact,
contrary to the official recommendation of antipsychotic monotherapy for the treatment of patients
with schizophrenia [22,51]. Our pharmacological data clearly illustrate the problem of heterogeneity
within the group of long-term patients with schizophrenia. Moreover, these data further stimulate
the ongoing clinical discussion of whether diagnostically one patient group with schizophrenia or all
kinds of groups with different subtypes of schizophrenia exist [52], as was described in the previous
versions of the Diagnostic and Statistical Manual of Mental disorders (DSM) classification system (e.g.,
DSM-IV [53], DSM-IV-TR [54]).
Secondly, we were interested in the question of whether our clinical sample of long-term
outpatients with schizophrenia suffered from sleep problems. We expected that this would, indeed, be
the case. If we look at our data, the results of the subjective sleep quality inventories show that the
patients scored above the generally used cut-off score of 5 [45], as well as above the more recently used
stricter cut-off score of 6 [48], meaning that they are poor sleepers. Here, noting that these patients
scored above the cut-off scores despite their ongoing pharmacological treatment is important. Probably,
without this pharmacological treatment, particularly their specific sleep medication and the medication
that enhanced their sleep, their sleep problems would have been even worse. Moreover, this finding
shows that the ongoing pharmacological treatment is unable to adequately treat the sleep problems in
this patient group and that further improvements in the disease management of the co-morbid sleep
disorders are needed. With respect to the second subjective sleep inventory that measured daytime
sleepiness, the long-term patients with schizophrenia scored below the generally used cut-off score
of 9 [46], meaning that they did not suffer from daytime sleepiness in comparison with the healthy
norm. With respect to daytime sleepiness, the ongoing pharmacological treatment of the patients
did not seem to increase their sleepiness, as might have been expected, because sleepiness has often
been mentioned as a side effect [55,56]. Nevertheless, in the future, the pharmacological treatment
may be further improved so that long-term male and female patients with schizophrenia, on average,
score close to 0 on the ESS instead of around the value of 6 at present. Moreover, noting that almost
one out of three (14/45 = 31.11%) of our patients still reported suffering from daytime sleepiness
(ESS scores > 9), which is a significant number, is important.
Our third hypothesis was that an interaction between the pharmacological treatment and the
subjective quality of sleep was expected to exist. Overall, the results from this study regarding the
correlation between the pharmacological treatment and the subjective quality of sleep are mixed,
depending on whether the focus is on the broad spectrum of sleep problems, as measured with the
PSQI [45], or on daytime sleepiness specifically, as measured with the ESS [46]. First, when looking at
the PSQI results [45], no correlation between the pharmacological treatment and the scores on the PSQI
was found. This can be explained as follows: Some patients seem to benefit from the use of drugs [26],
whereas other patients have negative sleep effects due to the pharmacological treatment [26]. When all
pharmacological data are taken together, the positive and the negative effects of the use of drugs
seem to counterbalance, so no significant positive or negative correlation is found. Our findings
are in line with the mixed findings that have been previously reported in the literature [26]. For
instance, the first-generation antipsychotics haloperidol, thiothixene, and flupentixol were found to
significantly reduce stage-two sleep latency and significantly increase sleep efficiency, whereas the
second-generation antipsychotics olanzapine, risperidone, and clozapine were found to significantly
increase both total sleep time and stage-two sleep [57]. However, our expections were fulfilled by our
data when looking at the daytime sleepiness results specifically. A positive relation was found between
the number of antipsychotic medications the patient used and the daytime drowsiness the patient
reported on the ESS [46]. The more antipsychotic medications the patient used, the more daytime
drowsiness the patient experienced.
An important difference exists between the ESS [46] and the PSQI [45]. The PSQI focuses
on the overall quality and quantity of sleep, as well as general sleepiness. The results show that
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those components seem to be altered in our subjects, no matter how many antipsychotics they take.
Those patients suffer from a generally dimished quality and quantity of sleep compared to the
healthy population, irrespective of the pharmacological treatment they receive. In contrast, the ESS
measures sleepiness while carrying out different activities during the day. Here, a higher number of
antipsychotics was found to go together with more drowsiness while doing those activities. Thus,
while the long-term patients with schizophrenia do generally show poorer quality of sleep, the number
of antipsychotics taken especially has a negative effect on daytime alertness and associated attention
and concentration. Due to the lack of alertness, those patients show an increased drowsiness and faster
exhaustion during daily activities. However, these are only speculations. If the sleep problems in
long-term patients withschizophrenia and the way in which pharmacological treatment affects the
quality of sleep in such patients are to be better understood, further investigations of exactly which
aspects of sleep are affected by the drugs are needed. Based on such knowledge, individual treatment
may be further improved.
Our fourth hypothesis was that gender differences will not be found in the pharmacological
treatment of long-term patients with schizophrenia because, according to the literature, such differences
are known to be often unaccounted for in clinical research [58] and in daily clinical practice [58].
The results of our study are clearly in line with our expectations. No significant differences between the
pharmacological treatments of males and females were found for the numbers of antipsychotics, sleep
medications, antidepressants, and anxiolytics. As already mentioned in the introduction, good reasons
exist for considering the gender of the patient when choosing the pharmacological treatment [59].
Research has shown that gender is a risk factor for side effects from certain medications [60].
Female patients were found to have at least a 1.5-fold greater risk of developing an adverse drug
reaction than male patients [61]. Thus, one drug or a combination of different medications can
have fundamentally different effects on male and female patients. However, as our studies found,
gender seems to be forgotten when prescribing medicines; thus, one can conclude that the side effects
suffered by patients can be reduced by taking into account the gender when planning the optimal
pharmacological treatment for the individual patient. In the future, this gap of knowledge needs to
be closed; studying the differences in the efficiencies of the medications between male and female
patients with schizophrenia is vital if the side effects of different drugs and the interactions between
different drugs are to be better controlled.
An important difference seems to exist between research and clinical practice with respect to
the pharmacological treatment of patients with schizophrenia and co-morbid sleep disorders, and
this difference needs to be eliminated. Although monotherapy is recommended [22], in daily clinical
practice, this is more the exception than the rule [22]. Patients often receive all kinds of antipsychotics
and sleep medications in order to deal with their positive, negative, and cognitive symptoms. Therefore,
many results obtained in scientific research are not directly transferrable to clinical practice.
A limitation of the present study is that the data were gathered in only one German psychiatric
clinic. As such, the general implications of our clinical study are limited, and it should be considered
as a pilot study. More data from other German psychiatric clinics, as well as larger international
multi-center studies, are needed in order to be able to draw firm conclusions that have more general
implications. For instance, different dosing of drugs for men and for women might be necessary. As an
example, in the specific case of zolpidem, The United States Food and Drug Administration required
labeling changes on 19 April 2013 [62]. It had previously been found that women have higher morning
serum zolpidem concentrations than men after taking an evening dose and this could lead to higher
risks of harm [63]. The present clinical study, however, was not large enough to suggest such changes.
Nevertheless, despite this limitation, the present study addresses several important issues, such as the
general importance of gender differences, which should be better taken into account in the study of
the clinical pharmacological treatment of patients with schizophrenia and co-morbid sleep disorders.
Another limitation of the current study is that some of the long-term patients with schizophrenia
were using caffeine and/or nicotine besides their pharmacological treatment. Previous research has
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shown that caffeine [64] and nicotine [65] have a disruptive effect on quality of sleep. In order to keep
our sample as close as possible to the daily clinical routine, it was chosen not to ask the patients about
their caffeine and/or nicotine consumption. The idea behind this was that such questioning could have
influenced the behavior of our patients because by asking them and making them alert of their caffeine
and/or nicotine consumption one uses a kind of clinical intervention. On the other hand, the amount
of caffeine and/or nicotine use of the individual patients could have been used as an important and
interesting covariate in our analyses of the relation between pharmacological treatment and the quality
of sleep as well as possible gender differences. For instance, previous research found that differences in
serum levels between male and female smokers exist after controlling for the amount of nicotine [66].
A third limitation of our study is that we focused only on long-term patients with schizophrenia.
In future research, including first-episode patients with schizophrenia as well would be interesting [67].
This would give better insight into the sleep problems experienced during the acute phase of psychosis.
For instance, collecting subjective [68] and objective [68] sleep data before any pharmacological
treatment has started and comparing these sleep data with the results after the pharmacological
treatment has started and at follow-up would be highly informative. Sleep problems seem to be an
important early warning sign for schizophrenia [69] and might be used as a marker for psychiatrists,
psychologists, nurses, etc. in clinical practice, as well as for relatives and friends in the social field of
the patient, to prevent upcoming psychotic relapses.
In addition, in future research it would be interesting to collect serum levels of the medication
taken [70]. In previous research, for instance, it has been observed that the serum levels of cytokine
IL-3 are significantly elevated in patients with long-term schizophrenia [71]. In this study, no serum
levels were collected, due to lack of funding. Moreover, it is not part of the standard care in our clinic
to collect serum levels of all medication at standard intervals; serum levels are measured when the
psychiatrist who treats a patient sees a necessity. For an overview of the exact medication that was
prescribed, we refer to Supplementary Table 1. In future studies, it would be beneficial to collect
serum levels in order to investigate the relationship between the subjective sleep assessments and the
medication [72].
Finally, it would have been interesting to analyze the pharmacological data at several time points
during a longer period of treatment [73]. The current study was not planned and approved for this
purpose; therefore, we were unfortunately unable to do this in the present study. However, in future
research, it would be highly interesting to include several measurement points [73] over a longer
period (e.g., for instance, additional measurements after six months, one year, two years, and four
years) since the pharmacological treatment of patients with long-term schizophrenia is not a static
but a dynamic process. This could provide important data on the changes in dosage and number of
medications over a longer treatment period; moreover, it could give important information about the
treatment compliance of the patients [73].
5. Conclusions
A large variability in the pharmacological treatment of long-term patients with schizophrenia
exists. To date, patients’ sleep problems have been insufficiently treated, and gender differences have
not been adequately accounted for. More and larger international clinical studies are warranted to
verify the findings of the present preliminary pilot study before any firm conclusions can be drawn
and before any changes to the drug treatment of male and female patients with schizophrenia can
be recommended.
Supplementary Materials: The following are available online at http://www.mdpi.com/2305-6320/5/2/44/s1,
Table S1: Overview of the medication use specified for gender, type of medications and dosage/day per long-term
outpatient suffering from schizophrenia.
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